Skip to main content
SpringerLink
Log in
Book cover

Interstitial Fibrosis in Heart Failure pp 329–341Cite as

Molecular Strategies for the Prevention of Cardiac Fibrosis

  • Chapter

  • 685 Accesses

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 253))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Weber, K.T., Cardiac interstititum. In Heart Failure: Scientific Principles and Clinical Practice, Poole-Wilson, P.A., Colucci, W.S., Massie, B.M., Chatterjee, K., Coats, A.J.S. eds. New York NY: Churchill Livingstone, 1997: p. 13–31.

    Google Scholar 

  2. Laurent, G. J., Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol, 1987.252: p. C1–9.

    PubMed  CAS  Google Scholar 

  3. Sun, Y., et al., Fibrous tissue and angiotensin II. J Mol Cell Cardiol, 1997.29: p. 2001–12.

    Article  PubMed  CAS  Google Scholar 

  4. Border, W. A. and N. A. Noble, Transforming growth factor beta in tissue fibrosis. N Engl J Med, 1994. 331: p. 1286–92.

    Article  PubMed  CAS  Google Scholar 

  5. Greenberg, B., Treatment of heart failure: state of the art and prospectives. J Cardiovasc Pharmacol, 2001. 38Suppl 2: p. S59–63.

    PubMed  CAS  Google Scholar 

  6. Zaman, M.A., S. Oparil, and D.A. Calhoun, Drugs targeting the renin-angiotensinaldosterone system. Nat Rev Drug Discov, 2002. 1: p. 621–36.

    Article  PubMed  CAS  Google Scholar 

  7. Rocha, R., et al., Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology, 2000. 141: p. 3871–8.

    Article  PubMed  CAS  ISI  Google Scholar 

  8. Modena, M.G., et al., Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J, 2001.141: p. 41–6.

    Article  PubMed  CAS  Google Scholar 

  9. Leonetti, G. and C. Cuspidi, Choosing the right ACE inhibitor. A guide to selection. Drugs, 1995. 49: p. 516–35.

    Article  PubMed  CAS  ISI  Google Scholar 

  10. Fabris, B., et al., Increased cardiac angiotensin-converting enzyme in rats with chronic heart failure. Clin Exp Pharmacol Physiol, 1990. 17: p. 309–14.

    PubMed  CAS  Google Scholar 

  11. Fabris, B., et al., Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats. Br J Pharmacol, 1990. 100: p. 651–5.

    PubMed  CAS  Google Scholar 

  12. Anon., Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med, 1991.325: p. 293–302.

    Google Scholar 

  13. Anon., Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med, 1992. 327: p. 669–677.

    Google Scholar 

  14. Pfeffer, M.A., et al., Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med, 1992. 327: p. 669–77.

    Article  PubMed  CAS  Google Scholar 

  15. St John Sutton, M., et al., Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation, 1997. 96: p. 3294–9.

    PubMed  CAS  Google Scholar 

  16. Konstam, M.A., et al., Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation, 1992. 86: p. 431–8.

    PubMed  CAS  ISI  Google Scholar 

  17. Weber, K.T., Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation, 1997. 96: p. 4065–82.

    PubMed  CAS  ISI  Google Scholar 

  18. Weber, K.T., et al., Angiotensin II and extracellular matrix homeostasis. Int J Biochem Cell Biol, 1999. 31: p. 395–403.

    Article  PubMed  CAS  Google Scholar 

  19. Weber, K.T., Angiotensin II and connective tissue: homeostasis and reciprocal regulation. RegulPept, 1999. 82: p. 1–17.

    CAS  Google Scholar 

  20. Brilla, C.G., L.S. Matsubara, and K.T. Weber, Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol, 1993. 25: p. 563–75.

    Article  PubMed  CAS  Google Scholar 

  21. Pitt, B., et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999. 341: p. 709–17.

    PubMed  CAS  Google Scholar 

  22. Zannad, F., et al., Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation, 2000. 102: p. 2700–6.

    PubMed  CAS  ISI  Google Scholar 

  23. Park, J.B. and E.L. Schiffrin, Cardiac and vascular fibrosis and hypertrophy in aldosteroneinfused rats: role of endothelin-1. Am J Hypertens, 2002. 15: p. 164–9.

    PubMed  CAS  Google Scholar 

  24. Ogata, T., et al., Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci, 2002. 103: p. 284S–288S.

    PubMed  CAS  Google Scholar 

  25. Rhaleb, N.E., et al., Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension, 2001. 37: p. 827–32.

    PubMed  CAS  ISI  Google Scholar 

  26. Fraccarollo, D., et al., Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling. Cardiovasc Res, 2002.54: p. 559–67.

    PubMed  CAS  Google Scholar 

  27. Huse, M., et al., The TGF beta receptor activation process: an inhibitor-to substratebinding switch. Mol Cell, 2001. 8: p. 671–82.

    Article  PubMed  CAS  Google Scholar 

  28. Hao, J., et al., Elevation of expression of Smads 2,3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol, 1999. 31: p. 667–78.

    Article  PubMed  CAS  Google Scholar 

  29. Laping, N.J., et al., Inhibition of transforming growth factor (TGF)-betal-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol, 2002. 62: p. 58–64.

    Article  PubMed  CAS  Google Scholar 

  30. Rodriguez-Barbero, A., et al., Transforming growth factor-betal induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts. FEBS Lett, 2002. 513: p. 282–8.

    PubMed  CAS  ISI  Google Scholar 

  31. McGaha, T.L., et al., Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol, 2002. 118: p. 461–70.

    Article  PubMed  CAS  Google Scholar 

  32. Dhalla, A.K., et al., chk-YB-1b, a Y-box binding protein activates transcription from rat alpha1 (I) procollagen gene promoter. Biochem J, 1998. 336: p. 373–9.

    PubMed  CAS  Google Scholar 

  33. Norman, J.T., et al., The Y-box binding protein YB-1 suppresses collagen alpha 1(1) gene transcription via an evolutionarily conserved regulatory element in the proximal promoter. J Biol Chem, 2001. 276: p. 29880–90.

    Article  PubMed  CAS  Google Scholar 

  34. Agrawal, S., Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta, 1999. 1489: p. 53–68.

    PubMed  CAS  Google Scholar 

  35. Opalinska, J.B. and A.M. Gewirtz, Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov, 2002. 1: p. 503–14.

    Article  PubMed  CAS  Google Scholar 

  36. Giovannangeli, C. and C. Helene, Triplex-forming molecules for modulation of DNA information processing. Curr Opin Mol Ther, 2000. 2: p. 288–96.

    PubMed  CAS  Google Scholar 

  37. Knauert, M.P. and P.M. Glazer, Triplex forming oligonucleotides: sequence-specific tools for gene targeting. Hum Mol Genet, 2001. 10: p. 2243–51.

    Article  PubMed  CAS  Google Scholar 

  38. Guntaka, R.V., B.R. Varma, and K.T. Weber, Triplex-forming oligonucleotides as modulators of gene expression. Int J Biochem Cell Biol, 2003. 35: p. 22–31.

    Article  PubMed  CAS  Google Scholar 

  39. Roque, F., et al,, Safety of intracoronary administration of c-myc antisense oligomers after percutaneous transluminal coronary angioplasty (PTCA). Antisense Nucleic Acid Drug Dev, 2001. 11: p. 99–106.

    Article  PubMed  CAS  ISI  Google Scholar 

  40. Kutryk, M.J., et al., Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting trial. J Am Coll Cardiol, 2002. 39: p. 281–7.

    Article  PubMed  CAS  Google Scholar 

  41. Swamynathan, S.K., et al., Targeted disruption of one allele of the Y-box protein gene, Chk-YB-1b, in DT40 cells results in major defects in cell cycle. Biochem Biophys Res Commun, 2002. 296: p. 451–7.

    Article  PubMed  CAS  Google Scholar 

  42. Weiss, R.H. and C.J. Randour, Attenuation of matrix protein secretion by antisense oligodeoxynucleotides to the cyclin kinase inhibitor p21(Waf1/Cip1). Atherosclerosis, 2002. 161: p. 105–12.

    Article  PubMed  CAS  ISI  Google Scholar 

  43. Kovacs, A., et al., Triple helix-forming oligonucleotide corresponding to the polypyrimidine sequence in the rat alpha 1 (I) collagen promoter specifically inhibits factor binding and transcription. J Biol Chem, 1996. 271: p. 1805–12.

    PubMed  CAS  Google Scholar 

  44. Joseph, J., et al., Antiparallel polypurine phosphorothioate oligonucleotides form stable triplexes with the rat alpha1(I) collagen gene promoter and inhibit transcription in cultured rat fibroblasts. Nucleic Acids Res, 1997. 25: p. 2182–8.

    Article  PubMed  CAS  ISI  Google Scholar 

  45. Nakanishi, M., K.T. Weber, and R. V. Guntaka, Triple helix formation with the promoter of human alpha1(I) procollagen gene by an antiparallel triplex-forming oligodeoxyribonucleotide. Nucleic Acids Res, 1998. 26: p. 5218–22.

    Article  PubMed  CAS  ISI  Google Scholar 

  46. Franklin, T.J., et al., Inhibition of prolyl 4-hydroxylase in vitro and in vivo by members of a novel series of phenanthrolinones. Biochem J, 2001. 353: p. 333–8.

    PubMed  CAS  Google Scholar 

  47. Nwogu, J.I., et al., Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation, 2001. 104: p. 2216–21.

    PubMed  CAS  ISI  Google Scholar 

  48. Siddiqui-Jain, A., et al., Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci U S A, 2002. 99: p.11593–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA

    Ramareddy V. Guntaka & Karl T. Weber

Authors
  1. Ramareddy V. Guntaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karl T. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, University of California, San Diego School of Medicine, San Diego, California, USA

    Francisco J. Villarreal M.D., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science + Business Media, Inc.

About this chapter

Cite this chapter

Guntaka, R.V., Weber, K.T. (2005). Molecular Strategies for the Prevention of Cardiac Fibrosis. In: Villarreal, F.J. (eds) Interstitial Fibrosis in Heart Failure. Developments in Cardiovascular Medicine, vol 253. Springer, New York, NY. https://doi.org/10.1007/0-387-22825-X_16

Download citation

  • DOI: https://doi.org/10.1007/0-387-22825-X_16

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-22824-2

  • Online ISBN: 978-0-387-22825-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation